BioMarin to acquire Prosensa

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has concluded it can successfully make the case to gain approval for drisapersen to treat Duchenne muscular dystrophy after it acquires Prosensa Holding N.V. (NASDAQ:RNA) for $680 million in cash up front and up to $160 million in milestones.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) returned rights to drisapersen to Prosensa in January, ending a 2009 licensing deal, after the compound missed the primary endpoint of improving 6-minute walk distance (6MWD) from baseline to week 48 vs. placebo (see BioCentury, Sept. 30, 2013). ...